This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Head & Neck Cancer  • Neoplasms of Head & Neck  • Pathology of Head & Neck  • Diagnosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Christine G. Gourin, MD; William H. Moretz III, MD; Paul M. Weinberger, MD; Zhong-Sheng Xia, MD; Zhongmin Liu, PhD; David J. Terris, MD; Bao-Ling Adam, PhD

Arch Otolaryngol Head Neck Surg. 2007;133(11):1125-1130.

Objective  To determine the sensitivity and specificity of surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) assay for head and neck squamous cell carcinoma (HNSCC) disease surveillance.

Design  The SELDI-TOF-MS serum protein profiles of patients with HNSCC were analyzed to determine the sensitivity and specificity of the SELDI assay for HNSCC detection following definitive treatment.

Setting  Academic research.

Patients  Thirty-two patients with previously untreated HNSCC.

Intervention  Serum samples were collected prospectively at 3-month intervals following treatment during a 24-month follow-up period.

Main Outcome Measures  Ninety-three serum samples were analyzed.

Results  The SELDI-TOF-MS identified protein peaks in the range of 0 to 100 kDa. Classification tree analysis based on peak expression distinguished pretreatment from 6-month posttreatment samples with 75.0% sensitivity and 87.5% specificity. Samples collected at 3 months following treatment did not significantly differ from pretreatment samples. Serum samples from patients who were disease free at 6 months or longer following treatment differed from matched pretreatment samples by the overexpression of a protein peak at 6495 Da, while serum samples from patients with recurrence differed from matched pretreatment samples by the underexpression of a protein peak at 4493 Da.

Conclusions  Proteomic analysis of serum protein profiles distinguishes pretreatment and posttreatment samples from patients with HNSCC with a high degree of sensitivity and specificity. After 6 months, serum protein profiles seem to have distinct differences in peak expression based on disease status. Further investigation of the clinical usefulness of this technology in HNSCC detection and surveillance is warranted.

Author Affiliations: Department of Otolaryngology–Head and Neck Surgery (Drs Gourin, Moretz, Weinberger, Terris, and Adam) and Center for Biotechnology and Genomic Medicine (Drs Xia, Liu, and Adam), Medical College of Georgia, Augusta.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?